Auranofin

金诺芬

Report date: 2026/03/10 20:00:16
NME

Base Information

Drug NameAuranofin
Drug Alias NameAuranofinum醋硫葡金auranofinaauranofineRidauran +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInhibitor of NF-kappa-B kinase (IKK) inhibitors
TargetsInhibitor of NF-kappa-B kinase (IKK)
Therapy Area/IndicationsPainArthritis, RheumatoidLeukemia, Prolymphocytic +[8] 
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1985/05/24
Country/TerritoryUnited StatesBangladesh
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSebela Ireland Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLegacy Pharma Inc
Inactive CompaniesVaccine And Gene Therapy InstituteNational Cancer InstituteNational Institute Of Allergy And Infectious Diseases (Niaid) +[4] 
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsPainLeukemia, ProlymphocyticLeukemia, Lymphocytic, Chronic, B-Cell +[7] 

Other Information

ATC CodeM01CB03
Related LinksWikipediaDrugBankKEGG